FSD Pharma Inc. | WebDisclosure

Basculer en Français

10365	Companies
215854	Keywords
145586	Articles
114300	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 1 month ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 1 month ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 1 month ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 1 month ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 2 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 2 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 2 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 2 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 2 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 2 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 05/07/2026 at 15:15, 8 minutes ago

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 48 minutes ago

Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 53 minutes ago

Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 14:30, 53 minutes ago

Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook
Published on 05/07/2026 at 14:00, 1 hour 23 minutes ago

Adcore to Publish First Quarter 2026 Results on May 14, 2026

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 15:10, 12 minutes ago

Elevated Materials Appoints Sunit Kapur as Chief Operating Officer
Published on 05/07/2026 at 15:05, 17 minutes ago

CELEBRATING FEET WITH A TOUCH OF COLOR: BIRKENSTOCK INTRODUCES NAIL POLISH COLLECTION
Published on 05/07/2026 at 14:56, 26 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/07/2026 at 14:54, 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/07/2026 at 14:53, 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc

Les Echos

Published on 05/07/2026 at 15:00, 23 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 05/07/2026 at 07:43, 7 hours 39 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/07/2026 at 07:43, 7 hours 39 minutes ago

ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 21 hours 23 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 21 hours 23 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026

View all LES ECHOS COMFI WIRE